Company: SXTPW
Filing Date: 2025-01-30
Form Type: 424B5
Source: 0001213900-25-008098
Chunk: 34

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-01-30
Form: 424B5
Chunk 34
---
END POLICY</div>

We have not declared any cash dividends since inception and we do not anticipate paying any dividends in the foreseeable future. Instead, we anticipate that all of our earnings will be used to provide working capital, to support our operations, and to finance the growth and development of our business, including potentially the acquisition of, or investment in, businesses, technologies or products that complement our existing business. The payment of dividends is within the discretion of the Board and will depend on our earnings, capital requirements, financial condition, prospects, applicable Delaware law, which provides that dividends are only payable out of surplus or current net profits, and other factors our Board might deem relevant. There are no restrictions that currently limit our ability to pay dividends on our common stock other than those generally imposed by applicable state law.

<div align='center'>CAPITALIZATION</div>

The following table sets forth our consolidated cash and capitalization, as of September 30, 2024. Such information is set forth on the following basis:

| ● | on an actual basis;                                                                                                                |
| ● | on a pro forma basis to                                                                                                            
 reflect the issuance of (i) 79,040 shares issued to our officers as 2024 bonuses and (ii) 2,454,551 shares issued for the exercise 
 of 2,454,551 pre-funded warrants after September 30, 2024 but prior to the date of this prospectus supplement; and                 |

| ● | on a pro forma as adjusted                                                                                                           
 basis to reflect our receipt of the net proceeds our sale and issuance of 1,021,549 shares of common stock in this offering          
 based on the public offering price of $1.021 per share of common stock, after deducting estimated Placement Agent fees and estimated 
 offering expenses of approximately $240,000 payable by us and after the use of net proceeds therefrom.                               |

<div align='center'>S-21</div>

You should read the following table in conjunction with “ Use of Proceeds,” “ Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our financial statements and related notes included in this prospectus. The following table sets forth our cash, cash equivalents and short-term investments and capitalization as of September 30, 2024 (in thousands):

|                                                                                                                                     |     | Actual |             |   |     | Pro Forma(1) |             |   |     | Pro Forma      
 as adjusted(1) |             |   |
|: